Schizophrenia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Signed and dated informed consent document indicating that the patient is willing to participate in the trial and receive the treatment; 2. Female or male outpatients /inpatients, 18-45 years of age; 3. Meet the description of schizophrenia in the DSM-V; 4. There are still positive symptoms and the social functions having not recovered to the status before disease onset despite treatment with adequate doses and duration of 2 antipsychotics (6w) within 5 years; 5. BPRS>45, and PANSS>60;6. Be able to understand and follow the investigators requirements in the investigators opinion.
Exclusion criteria
Exclusion criteria: 1. Poor efficacy achieved in the previous treatment with adequate doses of Clozapine, Paliperidone and Olanzapine, or allergy to Paliperidone and Olanzapine; 2. Alcohol or drug dependence; 3. On electric shock treatment in recent 3 months; 4. Suicidal tendency (including suicide idea); 5. Patients with epilepsy or acute cerebrovascular diseases; 6. Patients with severe physical diseases of the nervous system, heart, liver, kidney, endocrine system and blood system, etc., or other disease may interfere with the assessment of the clinical trial; 7. Patients with organic mental disorders or mental retardation; 8. Women who are pregnant or breastfeeding, or women of childbearing potential who are about to get pregnant; 9. Neutrophil absolute count <1.5 x 109/L in the screening; 10. QTC interval =500ms, or other significant ECG events with clinical significance according to the investigator’s opinion; 11. Patients with other conditions that investigator considers ineligible for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| PSP;BPRS;CGI;cognitive function; | — |
Contacts
First Affiliated Hospital, Zhejiang University School of Medicine